Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib + Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT02235740Phase 1Terminated
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of afuresertib in multiple myeloma (MM) (5 arms), sponsored by Novartis. Primary endpoints: Adverse Events and Progression Free Survival. Started Nov 2014; status: terminated.
02
Drugs
afuresertib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02235740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235740.